Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.
U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.
Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.
PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.
TransCelerate BioPharma, a nonprofit founded by the world's biggest drugmakers to make R&D more efficient, is encouraging developers to adopt risk-based monitoring for clinical trials, disclosing its thinking in two research papers.
Pennsylvania CRO FlowMetric is zeroing in on companion diagnostics, launching a new company to put its platform technology to use in developing tests.
The Association of Clinical Research Organizations, which represents the world's largest CROs, polled its membership and found that the industry's biggest players have seen their revenues and payrolls skyrocket over the past decade, claiming an increasingly large share of global R&D spends.
PCI, a contract pharma packaging company, has snapped up clinical trial supply operation Biotec, expanding its footprint across all phases of drug development.